Lung infections. 3. Pseudomonas aeruginosa and other related species.
Wilson
R
R
Host Defence Unit, Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, UK.
Dowling
R B
RB
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000382:microbiology; D004352:Drug Resistance, Microbial; D006801:Humans; D007249:Inflammation; D009894:Opportunistic Infections / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D011552:Pseudomonas Infections / Q000276:immunology* / Q000628:therapy; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000382:microbiology* / Q000628:therapy
D000900:Anti-Bacterial Agents